AbbVie Inc (ABBV)vsSeres Therapeutics Inc (MCRB)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
MCRB
Seres Therapeutics Inc
$7.05
-0.56%
HEALTHCARE · Cap: $67.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7751485% more annual revenue ($61.16B vs $789,000). MCRB leads profitability with a 722.0% profit margin vs 6.9%. MCRB trades at a lower P/E of 11.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MCRB
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for MCRB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Keeps 722 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Revenue declined 93.4%
Earnings declined 91.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MCRB
The strongest argument for MCRB centers on P/E Ratio, Profit Margin, Price/Book. Profitability is solid with margins at 722.0% and operating margin at -4424.0%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MCRB
The primary concerns for MCRB are Market Cap, Debt/Equity, Revenue Growth. Debt-to-equity of 1.95 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while MCRB is a declining play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 35/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Seres Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?